公开(公告)号：US20130143880A1

公开(公告)日：2013-06-06

申请号：US13814870

申请日：2011-08-05

申请人： Vadim Y. Dudkin ,  Mark E. Fraley ,  Kenneth L. Arrington ,  Mark E. Layton ,  Alexander J. Reif ,  Kevin J. Rodzinak ,  Joseph E. Pero

发明人： Vadim Y. Dudkin ,  Mark E. Fraley ,  Kenneth L. Arrington ,  Mark E. Layton ,  Alexander J. Reif ,  Kevin J. Rodzinak ,  Joseph E. Pero

IPC分类号： A61K31/4745 ,  C07D235/26 ,  A61K31/4439 ,  C07D417/14 ,  C07D405/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/10 ,  C07D413/10 ,  C07D409/10 ,  C07D405/10 ,  A61K31/4184 ,  C07D413/02 ,  C07D401/02 ,  C07D403/02 ,  A61K31/4709 ,  C07D471/04

CPC分类号： C07D235/26 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/06 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/14 ,  C07D453/02 ,  C07D471/04 ,  C07D513/14

摘要： The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved, such as schizophrenia.

摘要翻译： 本发明涉及作为mGluR2受体的正变构调节剂的苯并咪唑酮衍生物，其可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及mGluR2受体的疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病如精神分裂症中的用途。

公开(公告)号：US08993779B2

公开(公告)日：2015-03-31

申请号：US13814870

申请日：2011-08-05

申请人： Vadim Y. Dudkin ,  Mark E. Fraley ,  Kenneth L. Arrington ,  Mark E. Layton ,  Alexander J. Reif ,  Kevin J. Rodzinak ,  Joseph E. Pero

发明人： Vadim Y. Dudkin ,  Mark E. Fraley ,  Kenneth L. Arrington ,  Mark E. Layton ,  Alexander J. Reif ,  Kevin J. Rodzinak ,  Joseph E. Pero

IPC分类号： C07D235/26 ,  C07D417/14 ,  C07D403/04 ,  C07D403/14 ,  C07D401/04 ,  C07D401/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D403/10 ,  C07D405/06 ,  C07D453/02 ,  C07D513/14 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D471/04

CPC分类号： C07D235/26 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/06 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/14 ,  C07D453/02 ,  C07D471/04 ,  C07D513/14

摘要： The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved, such as schizophrenia.

摘要翻译： 本发明涉及作为mGluR2受体的正变构调节剂的苯并咪唑酮衍生物，其可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及mGluR2受体的疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病如精神分裂症中的用途。

公开(公告)号：US20130210768A1

公开(公告)日：2013-08-15

申请号：US13701039

申请日：2011-06-06

申请人： Kenneth L. Arrington ,  Vadim Dudkin ,  Mark E. Layton ,  Joseph E. Pero ,  Alexander J. Reif

发明人： Kenneth L. Arrington ,  Vadim Dudkin ,  Mark E. Layton ,  Joseph E. Pero ,  Alexander J. Reif

IPC分类号： C07D471/04 ,  C07F7/10 ,  C07D519/00

CPC分类号： C07D471/04 ,  C07D519/00 ,  C07F7/10

摘要： The present invention is directed to 5-substituted 1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-one derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved, such as schizophrenia.

摘要翻译： 本发明涉及作为mGluR2受体的正变构调节剂的5-取代的1,3-二氢-2H-咪唑并[4,5-b]吡啶-2-酮衍生物，其可用于治疗或预防神经和 与谷氨酸功能障碍相关的精神疾病和涉及mGluR2受体的疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病如精神分裂症中的用途。

公开(公告)号：US08765784B2

公开(公告)日：2014-07-01

申请号：US13701039

申请日：2011-06-06

申请人： Kenneth L. Arrington ,  Vadim Dudkin ,  Mark E. Layton ,  Joseph E. Pero ,  Alexander J. Reif

发明人： Kenneth L. Arrington ,  Vadim Dudkin ,  Mark E. Layton ,  Joseph E. Pero ,  Alexander J. Reif

IPC分类号： C07D471/04 ,  A61K31/415

CPC分类号： C07D471/04 ,  C07D519/00 ,  C07F7/10

摘要： The present invention is directed to 5-substituted 1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-one derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved, such as schizophrenia.

摘要翻译： 本发明涉及作为mGluR2受体的正变构调节剂的5-取代的1,3-二氢-2H-咪唑并[4,5-b]吡啶-2-酮衍生物，其可用于治疗或预防神经和 与谷氨酸功能障碍相关的精神疾病和涉及mGluR2受体的疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病如精神分裂症中的用途。

公开(公告)号：US09315518B2

公开(公告)日：2016-04-19

申请号：US14125813

申请日：2012-06-14

申请人： Hannah D. Fiji ,  Michael J. Kelly, III ,  Jeffrey C. Kern ,  Mark E. Layton ,  Joseph E. Pero ,  Alexander J. Reif ,  Michael A. Rossi

发明人： Hannah D. Fiji ,  Michael J. Kelly, III ,  Jeffrey C. Kern ,  Mark E. Layton ,  Joseph E. Pero ,  Alexander J. Reif ,  Michael A. Rossi

IPC分类号： C07D513/04 ,  C07D471/04 ,  C07D519/00

CPC分类号： C07D513/04 ,  C07D471/04 ,  C07D519/00

摘要： The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

摘要翻译： 本发明涉及作为代谢型谷氨酸受体，特别是mGluR2受体的增强剂的咪唑并吡啶-2-酮衍生物，其可用于治疗或预防与谷氨酸功能障碍相关的神经和精神病学障碍以及代谢型谷氨酸受体 涉及。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病中的用途。

公开(公告)号：US20140350002A1

公开(公告)日：2014-11-27

申请号：US14125813

申请日：2012-06-14

申请人： Hannah D. Fiji ,  Michael J. Kelly, III ,  Jeffrey C. Kern ,  Mark E. Layton ,  Joseph E. Pero ,  Alexander J. Reif ,  Michael A. Rossi

发明人： Hannah D. Fiji ,  Michael J. Kelly, III ,  Jeffrey C. Kern ,  Mark E. Layton ,  Joseph E. Pero ,  Alexander J. Reif ,  Michael A. Rossi

IPC分类号： C07D513/04 ,  C07D471/04

CPC分类号： C07D513/04 ,  C07D471/04 ,  C07D519/00

摘要： The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

摘要翻译： 本发明涉及作为代谢型谷氨酸受体，特别是mGluR2受体的增强剂的咪唑并吡啶-2-酮衍生物，其可用于治疗或预防与谷氨酸功能障碍相关的神经和精神病学障碍以及代谢型谷氨酸受体 涉及。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病中的用途。